Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

MLA

Michael L, Wang, et al. “Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.” New England Journal of Medicine, vol. 386, June 2022, pp. 2482–94. EBSCOhost, https://doi.org/10.1056/nejmoa2201817.

APA

Michael L, W., Wojciech, J., Mats, J., Judith, T., Pier L, Z., David, B., Carola, B., Ian W, F., Pratyush, G., Andre, G., Paul A, H., Olivier, H., José-Ángel, H.-R., Xiaonan, H., Seok Jin, K., David, L., Yuko, M., Muhit, Ö., Guilherme F, P., … Joseph C, G. (2022). Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. New England Journal of Medicine, 386, 2482–2494. https://doi.org/10.1056/nejmoa2201817

Chicago

Michael L, Wang, Jurczak Wojciech, Jerkeman Mats, Trotman Judith, Zinzani Pier L, Belada David, Boccomini Carola, et al. 2022. “Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.” New England Journal of Medicine 386 (June): 2482–94. doi:10.1056/nejmoa2201817.